HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Emerging Generic Competition for Tofacitinib: Strategic Implications for Market Players

Intelligence briefing

Intelligence Briefing · ~5 min read

Emerging Generic Competition for Tofacitinib: Strategic Implications for Market Players

Immunology · JAK Inhibitor

Type

Regulatory Context Briefing

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 72%

Evidence

12 items

Sources

12

Key Takeaways

Leadership-ready summary — read in 5 minutes.

  • Regulatory risk is concentrated around FDA AP — TOFACITINIB CITRATE (ORIG) (FDA). Entity match (tofacitinib citrate); Regulatory pathway relevance (nda).
  • Elevated regulatory exposure could delay market entry or constrain labeling for new entrants.
  • Competitive pressure on Saptalis Pharmaceuticals: This approval introduces a generic competitor to the market, potentially impacting the sales of the branded product and.
  • Competitive pressure on SPECGX LLC: This approval allows SPECGX LLC to enter the market with a generic version of Tofacitinib, potentially increasing compet.
  • Competitive pressure on Macleods Pharmaceuticals: This approval allows Macleods to enter the market with a generic version of Tofacitinib, increasing competition against.

Why It Matters

Strategic context for leadership and portfolio decision-making.

Regulatory risk is concentrated around FDA AP — TOFACITINIB CITRATE (ORIG) (FDA). Entity match (tofacitinib citrate); Regulatory pathway relevance (nda).

Supporting Evidence

Evidence-backed items from the Humanexa intelligence graph.

  • FDA Grants Approval for Tofacitinib Citrate ANDA219395

    Immunology · JAK Inhibitor

    Source: Regulatory Approval

    View evidence

  • FDA Grants Approval for Tofacitinib Citrate ANDA219530 by Macleods Pharmaceuticals

    Immunology · JAK Inhibitor

    Source: Regulatory Approval

    View evidence

  • FDA Approves ANDA for Tofacitinib Citrate by MSN

    Immunology · JAK Inhibitor

    Source: Regulatory Approval

    View evidence

  • FDA Grants Approval for Tofacitinib Citrate ANDA219830 by Orient Pharma

    Immunology · JAK Inhibitor

    Source: Regulatory Approval

    View evidence

  • FDA Approves ANDA for Tofacitinib Citrate by Auson

    Immunology · JAK Inhibitor

    Source: Regulatory Approval

    View evidence

  • FDA Grants Approval for Tofacitinib Citrate ANDA218821 by Concord Biotech

    Immunology · JAK Inhibitor

    Source: Regulatory Approval

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Grants Approval for Tofacitinib Citrate ANDA219395

    Immunology · JAK Inhibitor

  • FDA Grants Approval for Tofacitinib Citrate ANDA219530 by Macleods Pharmaceuticals

    Immunology · JAK Inhibitor

  • FDA Approves ANDA for Tofacitinib Citrate by MSN

    Immunology · JAK Inhibitor

  • FDA Grants Approval for Tofacitinib Citrate ANDA219830 by Orient Pharma

    Immunology · JAK Inhibitor

  • FDA Approves ANDA for Tofacitinib Citrate by Auson

    Immunology · JAK Inhibitor

  • FDA Grants Approval for Tofacitinib Citrate ANDA218821 by Concord Biotech

    Immunology · JAK Inhibitor

  • FDA Grants Approval for Tofacitinib Citrate ANDA218900 by Saptalis Pharmaceuticals

    Immunology · JAK Inhibitor

Insights

  • Emerging Generic Competition for Tofacitinib: Strategic Implications for Market Players

    Immunology · JAK Inhibitor

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.